- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Xilio Therapeutics Inc (XLO)
The Xilio Therapeutics share price today is 9.190, view NASDAQ XLO stock exchange data. Track the latest Xilio Therapeutics share price with real-time updates on XLO stock performance including market cap, day range, 52-week range and dividend yield. Access XLO charts, earnings dates and analyst estimates to support your investment decisions.
9.190
-0.120(-1.29%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.140
9.375
52 wk Range
6.465
12.739
XLO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.1409.375
52 wk Range
6.46512.739
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
XLO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
20.000
Upside
+117.63%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form S-3 Xilio Development Inc For: 12 May
- Investing.com
- Form 8K Xilio Development Inc For: 12 May
- Investing.com
- Form 4 Xilio Therapeutics Inc For: 12 June
- Investing.com
- Form 4 Xilio Therapeutics Inc For: 12 June
- Investing.com
- Form S-3/A Xilio Development Inc For: 27 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 20.000
(+117.63% Upside)
Earnings
Latest Release
12-05-2026
EPS / Forecast
-0.58 / -0.07
Revenue / Forecast
12.65M / 10.9M
Compare XLO to Peers and Sector
Metrics to compare | XLO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXLOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.8x | −9.2x | −0.4x | |
PEG Ratio | −0.03 | 0.00 | 0.00 | |
Price/Book | 0.8x | 3.3x | 2.6x | |
Price / LTM Sales | 1.0x | 8.6x | 3.0x | |
Upside (Analyst Target) | 114.8% | 37.9% | 49.7% | |
Fair Value Upside | Unlock | −13.1% | 7.3% | Unlock |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Xilio Therapeutics (XLO) Share Price Today?
The Xilio Therapeutics share price today is 9.190.
What is the current Xilio Therapeutics (XLO) share price and day range?
As of 08-07-2026, the Xilio Therapeutics share price is 9.190, with a previous close of 9.310. The share price has ranged from 9.140 to 9.375 today, while the 52-week range spans from 6.465 to 12.739.
What Is the Xilio Therapeutics Market Cap?
As of today, Xilio Therapeutics market cap is 55.700M.
What Is the Xilio Therapeutics (XLO) Share Price Target?
The average 12-month share price target for Xilio Therapeutics is 20.000, with a high estimate of 20 and a low estimate of 20. 1 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +117.63% Upside potential.
What Is Xilio Therapeutics's Earnings Per Share (TTM)?
The Xilio Therapeutics EPS (TTM) is -5.413.
When Is the Next Xilio Therapeutics Earnings Date?
Xilio Therapeutics will release its next earnings report on 12-08-2026.
From a Technical Analysis Perspective, Is XLO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Xilio Therapeutics Trade On?
Xilio Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Xilio Therapeutics?
The stock symbol for Xilio Therapeutics is "XLO."
How Many Times Has Xilio Therapeutics Stock Split?
Xilio Therapeutics has split 1 times.
How Many Employees Does Xilio Therapeutics Have?
Xilio Therapeutics has 76 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.